PacBio Files 8-K/A Amendment on Leadership Changes

Ticker: PACB · Form: 8-K/A · Filed: 2024-12-13T00:00:00.000Z

Sentiment: neutral

Topics: leadership-change, executive-compensation, amendment

Related Tickers: PACB

TL;DR

**PacBio amends 8-K, signaling leadership shifts and exec comp changes.**

AI Summary

Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on November 11, 2024, related to the departure of directors, election of directors, appointment of officers, and compensatory arrangements. The filing details changes within the company's leadership and executive compensation structure.

Why It Matters

This amendment provides updated information on the company's board of directors and executive officers, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: medium — Amendments to 8-K filings concerning director and officer changes, and compensatory arrangements, can indicate internal shifts that may affect company strategy and performance.

Key Players & Entities

FAQ

What specific leadership roles were affected by this amendment?

The filing pertains to the departure of directors, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

What is the exact date of the earliest event reported in this amendment?

The earliest event reported is dated November 11, 2024.

What form type is this filing?

This filing is a Form 8-K/A, which is an Amendment No. 1 to a Current Report.

What is the Commission File Number for Pacific Biosciences of California, Inc.?

The Commission File Number is 001-34899.

What is the SIC code for Pacific Biosciences of California, Inc.?

The Standard Industrial Classification (SIC) code is 3826, for Laboratory Analytical Instruments.

From the Filing

0001299130-24-000198.txt : 20241213 0001299130-24-000198.hdr.sgml : 20241213 20241213165100 ACCESSION NUMBER: 0001299130-24-000198 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241111 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241213 DATE AS OF CHANGE: 20241213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 241549104 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K/A 1 pacb-20241111.htm 8-K/A pacb-20241111 0001299130 true DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. 0001299130 2024-11-11 2024-11-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 11, 2024 Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) Delaware 001-34899 16-1590339 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code) ( 650 ) 521-8000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Explanatory Note As previously disclosed on a Form 8-K filed by Pacific Biosciences of California, Inc. (the “Company”) on November 12, 2024, the Company notified Jeff Eidel that, in connection with an internal restructuring of the commercial organization, he would separate from his position as the Chief Commercial Officer on November 15, 2024. This Form 8-K/A hereby

View on Read The Filing